These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 25347821)
21. The effects of Clostridium difficile crude toxins and toxin A on ileal and colonic loops in immune and non-immune rabbits. Ketley JM; Mitchell TJ; Candy DC; Burdon DW; Stephen J J Med Microbiol; 1987 Aug; 24(1):41-52. PubMed ID: 3612743 [TBL] [Abstract][Full Text] [Related]
22. Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin. Warn P; Thommes P; Sattar A; Corbett D; Flattery A; Zhang Z; Black T; Hernandez LD; Therien AG Antimicrob Agents Chemother; 2016 Nov; 60(11):6471-6482. PubMed ID: 27527088 [TBL] [Abstract][Full Text] [Related]
23. Interleukin-23 (IL-23), independent of IL-17 and IL-22, drives neutrophil recruitment and innate inflammation during Clostridium difficile colitis in mice. McDermott AJ; Falkowski NR; McDonald RA; Pandit CR; Young VB; Huffnagle GB Immunology; 2016 Jan; 147(1):114-24. PubMed ID: 26455347 [TBL] [Abstract][Full Text] [Related]
24. Effect of antisera from Clostridium difficile-infected mice on toxin-A-induced colonic epithelial cell death signaling. Kim DH; Lee IH; Nam ST; Nam HJ; Kang JK; Seok H; Hwang JS; Kim H J Microbiol Biotechnol; 2014 May; 24(5):696-703. PubMed ID: 24509250 [TBL] [Abstract][Full Text] [Related]
25. A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Davies NL; Compson JE; Mackenzie B; O'Dowd VL; Oxbrow AK; Heads JT; Turner A; Sarkar K; Dugdale SL; Jairaj M; Christodoulou L; Knight DE; Cross AS; Hervé KJ; Tyson KL; Hailu H; Doyle CB; Ellis M; Kriek M; Cox M; Page MJ; Moore AR; Lightwood DJ; Humphreys DP Clin Vaccine Immunol; 2013 Mar; 20(3):377-90. PubMed ID: 23324518 [TBL] [Abstract][Full Text] [Related]
26. Systemic and mucosal antibody responses to toxin A in patients infected with Clostridium difficile. Johnson S; Gerding DN; Janoff EN J Infect Dis; 1992 Dec; 166(6):1287-94. PubMed ID: 1431247 [TBL] [Abstract][Full Text] [Related]
27. Determination of the extent of Clostridium difficile colonisation and toxin accumulation in sows and neonatal piglets. Grześkowiak Ł; Zentek J; Vahjen W Anaerobe; 2016 Aug; 40():5-9. PubMed ID: 27108595 [TBL] [Abstract][Full Text] [Related]
28. Clostridium difficile: development of a novel candidate vaccine. Foglia G; Shah S; Luxemburger C; Pietrobon PJ Vaccine; 2012 Jun; 30(29):4307-9. PubMed ID: 22682287 [TBL] [Abstract][Full Text] [Related]
29. Recombinant lipoprotein-based vaccine candidates against C. difficile infections. Huang JH; Wu CW; Lien SP; Leng CH; Hsiao KN; Liu SJ; Chen HW; Siu LK; Chong P J Biomed Sci; 2015 Aug; 22(1):65. PubMed ID: 26245825 [TBL] [Abstract][Full Text] [Related]
31. Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine. Warny M; Fatimi A; Bostwick EF; Laine DC; Lebel F; LaMont JT; Pothoulakis C; Kelly CP Gut; 1999 Feb; 44(2):212-7. PubMed ID: 9895380 [TBL] [Abstract][Full Text] [Related]
32. Bacillus amyloliquefaciens as prophylactic treatment for Clostridium difficile-associated disease in a mouse model. Geeraerts S; Ducatelle R; Haesebrouck F; Van Immerseel F J Gastroenterol Hepatol; 2015 Aug; 30(8):1275-80. PubMed ID: 25800047 [TBL] [Abstract][Full Text] [Related]
33. Apoptosis of intestinal epithelial cells restricts Clostridium difficile infection in a model of pseudomembranous colitis. Saavedra PHV; Huang L; Ghazavi F; Kourula S; Vanden Berghe T; Takahashi N; Vandenabeele P; Lamkanfi M Nat Commun; 2018 Nov; 9(1):4846. PubMed ID: 30451870 [TBL] [Abstract][Full Text] [Related]
34. Sensitive assays enable detection of serum IgG antibodies against Clostridium difficile toxin A and toxin B in healthy subjects and patients with Clostridium difficile infection. Zhao X; Bender F; Shukla R; Kang JJ; Caro-Aguilar I; Laterza OF Bioanalysis; 2016 Apr; 8(7):611-23. PubMed ID: 26964649 [TBL] [Abstract][Full Text] [Related]
35. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. Yang Z; Schmidt D; Liu W; Li S; Shi L; Sheng J; Chen K; Yu H; Tremblay JM; Chen X; Piepenbrink KH; Sundberg EJ; Kelly CP; Bai G; Shoemaker CB; Feng H J Infect Dis; 2014 Sep; 210(6):964-72. PubMed ID: 24683195 [TBL] [Abstract][Full Text] [Related]
36. Preparation and preliminary application of monoclonal antibodies to the receptor binding region of Clostridium difficile toxin B. Chen W; Liu WE; Li YM; Luo S; Zhong YM Mol Med Rep; 2015 Nov; 12(5):7712-20. PubMed ID: 26459027 [TBL] [Abstract][Full Text] [Related]
37. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. Kyne L; Warny M; Qamar A; Kelly CP N Engl J Med; 2000 Feb; 342(6):390-7. PubMed ID: 10666429 [TBL] [Abstract][Full Text] [Related]
38. Identification of toxemia in patients with Clostridium difficile infection. Yu H; Chen K; Wu J; Yang Z; Shi L; Barlow LL; Aronoff DM; Garey KW; Savidge TC; von Rosenvinge EC; Kelly CP; Feng H PLoS One; 2015; 10(4):e0124235. PubMed ID: 25885671 [TBL] [Abstract][Full Text] [Related]